Pulmocide secures £17m in series-A

Imperial contributed £4.25m of the total amount and was joined in the funding round by SV Life Sciences (SVLS), Fidelity Biosciences and Johnson & Johnson Development Corporation (JJDC).

Fidelity, SVLS and Imperial were all backers of Respivert, the previous lung disease drug development company founded by members of Pulmocide's management team, namely CEO Garth Rapeport and CSO Peter Strong. Respivert was acquired by J&J in 2010, with Imperial reaping a 4.7x return on its original £2m investment three years prior.

Company
Founded this year, Pulmocide is based in London at the Imperial BioIncubator, a £7m facility set up by Imperial to provide office and laboratory space to start-ups operating in the life sciences industry.

Pulmocide is developing a range of inhaled medicines designed to treat viral and fungal infections of the respiratory tract, such as respiratory syncytial virus (RSV) and invasive aspergillosis, the latter of which is a fungal infection of the lungs that can be fatal.

People
Garth Rapeport is the CEO of Pulmocide. Maina Bhaman is a director of healthcare ventures at Imperial.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Early-stage
• Healthcare
• United Kingdom